Nasdaq GlobeNewswire

Apricus Biosciences Provides Corporate Update and Second Quarter 2017 Financial Results

Del

Vitaros Drug-Device Human Factor Studies Successfully Completed

Vitaros U.S. NDA Final Draft Completed with Re-Submission Expected in Current Quarter

Conference Call / Webcast Today, August 2, 2017 at 4:30 p.m. ET

SAN DIEGO, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported financial results for the second quarter of 2017 and provided a corporate update on its priorities for the remainder of the year.

"In the second quarter of this year, we continued to execute on our strategy by creating a stable, financially healthier organization focused on resubmission of the Vitaros NDA," stated Richard W. Pascoe, Chief Executive Officer. "We have improved our financial outlook through a combination of fundraising and expense reduction, resulting in a balance sheet that is expected to fund our current operating plan through the third quarter of 2018.  Importantly, we have completed the final draft of the Vitaros NDA and we expect to re-submit the Vitaros NDA this quarter with an anticipated FDA approval decision in the first quarter of 2018.  For the remainder of 2017, we will focus on working with the FDA regarding the Vitaros NDA, maintaining a productive dialogue with Allergan regarding the commercial potential for Vitaros in the United States, securing a development partner for RayVa, and continuing to diligently manage our corporate resources."

Recent Highlights

Apricus continues to execute on its corporate strategy as highlighted below:

Vitaros(TM) (alprostadil)

  • Continued implementation of the U.S. regulatory approval strategy to address issues raised by the FDA in the original Vitaros NDA submission.  Specifically, all safety, chemistry, manufacturing and control (CMC) related issues raised in the original Non-Approvable Letter will be addressed in the re-submission.  In addition, Apricus has confirmed the necessary drug-device engineering and compliance requirements, including human factor testing, and those studies are now complete; and
  • Continued to ensure a smooth transition of the Vitaros ex-US rights and assets to Ferring International.  Under the agreement, Apricus has received approximately $12.45 million to date, including an upfront payment of $11.5 million, approximately $0.7 million for the delivery of certain product-related inventory and $0.25 million related to transition services.  Apricus is eligible to receive an additional $0.25 million payment related to transition services, subject to certain limitations, during the third quarter of 2017.

RayVa(TM) (alprostadil)

  • Continued a partnering process to secure a global or regional RayVa partnership prior to initiating a Phase 2b clinical study.

Corporate/Financial

  • Closed on an underwritten public offering of common stock and warrants for gross proceeds of approximately $7.0 million; and
  • Regained compliance with all criteria for continued listing on The NASDAQ Capital Market.

Second Quarter and Year-to-Date Financial Results

Net loss for the quarter ended June 30, 2017 was $1.5 million, or loss per share of $0.13, compared to a net loss of $3.3 million, or loss per share of $0.54, for the second quarter of 2016. Net loss during the second quarter of 2017 was primarily due to expenses related to the preparation of our resubmission of the Vitaros NDA and other general and administrative expenses.

Net income for the six months ended June 30, 2017 was $6.6 million, or income per share of $0.69, compared to a net loss of $5.8 million, or loss per share of $1.00, for the second quarter of 2016. Net income during the six months ended June 30, 2017 was primarily due to the $12.1 million gain recorded for the sale of our ex-U.S. Vitaros rights and assets to Ferring.

For all periods presented, financial statement activity related to our ex-U.S. Vitaros business has been presented as discontinued operations.  As of June 30, 2017, the Company's cash totaled $7.8 million, compared to $2.1 million as of December 31, 2016.

Conference Call Details

Apricus will host a live conference call and webcast today at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a corporate update. To participate by telephone, please dial (855) 780-7196 (Domestic) or (631) 485-4867 (International).  The conference ID number is 58725002. The live and archived audio webcast can be accessed through the Investors Relations' section of the Company's website at www.apricusbio.com. Please log in approximately five to ten minutes before the event to ensure a timely connection. The archived webcast will be available for 30 days following the live call.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates currently in development. Vitaros is a product candidate in the United States for the treatment of erectile dysfunction, which is in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan). RayVa is our product candidate in Phase 2 development for the treatment of the circulatory disorder Raynaud's phenomenon, secondary to scleroderma, for which we own worldwide rights.

For further information on Apricus, visit http://www.apricusbio.com.

Vitaros(TM) is Apricus' trademark in the United States, which is pending registration and subject to the agreement with Allergan.  Vitaros® is a registered trademark of Ferring International Center S.A. in certain countries outside of the United States.  RayVa(TM) is Apricus' trademark, which is registered in certain countries throughout the world and pending registration in the United States.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act, as amended. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things: Apricus' ability to transition its ex-U.S. assets and rights related to Vitaros to Ferring and receive the second transition services payment from Ferring; the timing of regulatory submission and approval of Vitaros in the United States, if any; Apricus' development and partnering plans for RayVa; Apricus' plans to reduce operating expenses, including projected 2017 cost savings; and Apricus' strategic objectives. Actual results could differ from those projected in any forward-looking statements due to a variety of reasons that are outside the control of Apricus, including, but not limited to: the risk that Apricus fails to provide the transition services as required by the transition services agreement with Ferring; the risk that the cost and other negative effects related to the reduction of Apricus' workforce may be greater than anticipated; the risk that Apricus may not realize the benefits expected from cost control measures; competition in the erectile dysfunction market and other markets in which Apricus operates; Apricus' ability to obtain FDA and other requisite governmental approval for Vitaros; Apricus' ability to further develop Vitaros, such as delivery device improvements; Apricus' ability to carry out further clinical studies for Vitaros, if required, as well as the timing and success of the results of such studies; the failure to remain in compliance with NASDAQ continued listing requirements which could result in Apricus' common stock being delisted from the exchange; Apricus' ability to retain and attract key personnel; Apricus' ability to raise additional funding that it may need to continue to pursue its commercial and business development plans; Apricus' ability to secure a  strategic partner for RayVa; and market conditions. These forward-looking statements are made as of the date of this press release, and Apricus assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in Apricus' most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC's website at www.sec.gov or without charge from Apricus.

(Financial Information to Follow)


Selected Financial Information
Condensed Consolidated Statements of Operations
(In thousands, except per share amounts)
 
  Three Months Ended
 June 30,
  Six Months Ended
 June 30,
  2017   2016   2017   2016
Operating expense              
Research and development $ (839 )   $ (2,503 )   $ (1,266 )   $ (5,104 )
General and administrative (1,602 )   (2,122 )   (3,043 )   (4,328 )
Total other income (expense) 719     1,372     (832 )   3,684  
Loss from continuing operations (1,722 )   (3,253 )   (5,141 )   (5,748 )
Income (loss) from discontinued operations 248     (85 )   11,740     (95 )
Net income (loss) $ (1,474 )   $ (3,338 )   $ 6,599     $ (5,843 )
               
Basic and diluted earnings (loss) per share              
Continuing operations $ (0.15 )   $ (0.53 )   $ (0.54 )   $ (0.98 )
Discontinued operations $ 0.02     $ (0.01 )   $ 1.23     $ (0.02 )
Total earnings (loss) per share $ (0.13 )   $ (0.54 )   $ 0.69     $ (1.00 )
               
Weighted average common shares outstanding for basic and diluted earnings (loss) per share 11,335     6,182     9,547     5,843  

Condensed Consolidated Balance Sheets
(In thousands)
 
  June 30,
 2017
  December 31,
 2016
  (Unaudited)    
Assets      
Cash $ 7,821     $ 2,087  
Other current assets 322     177  
Property and equipment, net 121     164  
Other long term assets 45     60  
Assets of discontinued operations $ 506     $ 2,212  
Total assets $ 8,815     $ 4,700  
       
Liabilities and stockholders' equity (deficit)      
Current liabilities $ 1,513     $ 2,536  
Current liabilities of discontinued operations 331     2,108  
Notes payable, net -     6,650  
Warrant liabilities 339     846  
Other long term liabilities 60     76  
Stockholders' equity (deficit) 6,572     (7,516 )
Total liabilities and stockholders' equity (deficit) $ 8,815     $ 4,700  

CONTACT:

Matthew Beck
mbeck@troutgroup.com
The Trout Group
(646) 378-2933




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Apricus Biosciences, Inc. via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Leading Medical Organizations Update Guideline for Molecular Testing and Targeted Therapies in Lung Cancer23.1.2018 21:11Pressemelding

DENVER, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Rapid advancements in the molecular diagnostic testing of lung cancer have led to new treatments and greater hope for patients battling lung cancer, the most common cause of cancer death worldwide. To ensure that clinicians stay apace and provide optimal patient care, three leading medical societies-the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP)-have updated their 2013 evidence-based guideline. Published today in early online release, the "Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors," continues to set standards for the molecular analysis of lung cancers for test results that effectively guide targeted therapy and treatment. Targeted cancer therapies are drugs or other treatments that block the spread of cancer by interfering with specific molec

CashBet Seeks $40 Million for World's Only Complete Crypto-Ready Mobile iGaming Platform23.1.2018 16:31Pressemelding

Gaming and cryptocurrency industry leaders develop blockchain-based iGaming platform improving trust, speed, access, costs, and content availability OAKLAND, Calif., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Leading mobile-first iGaming platform provider CashBet (https://coin.cashbet.com/) today announced it seeks to raise $40 million through an Initial Coin Offering (ICO) to develop the world's first complete crypto-ready mobile iGaming platform. Interactive gaming, which includes real money, social, skill-based, esports and sports betting, hit $91 billion in 2016, led by mobile gaming. Despite strong growth, current iGaming operations continue to face three major issues: trust, speed, and cost. CashBet is the first and only vertically integrated iGaming solution to leverage blockchain technology for transparent operations, increased speed, and lower transaction fees. The CashBet Coin will be available in pre-sale starting January 24, 2018 at 5:00 p.m. GMT, with a 20 percent discount offered.

BrandSafway Announces Acquisition of Venko Groep BV23.1.2018 16:30Pressemelding

Combined customers to benefit from broader range of services and greater depth of expertise KENNESAW, GA, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Brand Industrial Services, known as BrandSafway, has acquired Venko Groep BV, a portfolio company of Mentha Capital, effective January 1, 2018. Moving forward, the company will operate as Venko, A BrandSafway Company and become a part of Brand Energy & Infrastructure Services (Brand) in Europe. "We're excited to announce the closing of the acquisition of Venko," said Dave Witsken, President of Energy and Industrial for BrandSafway. "Venko is a leading offshore coatings maintenance provider for platforms in Europe. By leveraging the highly specialized knowledge and capabilities of Venko, we will be able to provide expanded coatings services to Brand's European customers. At the same time, with our support, Venko will now be able to offer their customers a broader inventory of access equipment and additional industrial services, such as insulation an

Mitratech's TeamConnect Rated Most Widely Used Matter Management System in HBR Consulting's Annual Law Department Survey23.1.2018 15:00Pressemelding

HBR's Annual Survey further validates TeamConnect's market leadership AUSTIN, Texas, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Mitratech, the leading provider of legal, compliance, and risk management software solutions announced that TeamConnect, the market-leading ELM (enterprise legal management) platform, was rated the most widely used matter management system and the second most widely used e-Billing system in the 2017 HBR Consulting (HBR) Law Department Survey. HBR's Law Department Survey released this month rated Mitratech's TeamConnect as the most widely used system for matter management out of the 13 systems included in the survey. All told, Mitratech's ELM solutions accounted for more than a third of the matter management user base. TeamConnect also was rated for the third year in a row as the second most widely used e-Billing system, continuing a years-long trend of customers shifting to Mitratech's integrated ELM platform from other point solutions. Customer satisfaction continues

Data on Novel Humanized Models for Targeted Immunotherapy Development, a CrownBio Conference Talk on January 24th, 201823.1.2018 14:53Pressemelding

SAN DIEGO, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, will unveil data supporting use of its cost-effective, humanized drug target models at the Tumor Models Conference in San Francisco tomorrow, Wednesday, January 24th, 2018. Humanized research tools are crucial to the development of target-specific immunotherapies like pembrolizumab and ipilimumab. To help improve research in this burgeoning field, CrownBio has developed a humanized platform that informs the preclinical pharmacology of targeted immunotherapies, including solutions for PD-1, PD-L1, OX40, and CD3E. Constituent models feature fully functional murine immunity with humanized drug targets that can be used in conjunction with syngeneic tumor cell lines engineered to expr

Music Legend Joey Fatone Will Be Celebrity Grand Marshal Of First Ever 15th Annual World's Shortest St. Patrick's Day Parade In Hot Springs, Arkansas23.1.2018 13:56Pressemelding

HOT SPRINGS NATIONAL PARK, Ark., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Music legend Joey Fatone, who soared to worldwide fame as a member of boy-band *NSYNC, will be celebrity grand marshal of the First Ever 15th Annual World's Shortest St. Patrick's Day Parade in downtown Hot Springs March 17, 2018, reports Hot Springs Convention & Visitors Bureau. He'll round out a quartet of celebrities who will be part of the quirky parade, which annually draws throngs to world-famous Bridge Street, the shortest street in the world in everyday use - 98 feet long. Jon Heder, who became famous as Napoleon Dynamite, will be the parade's official starter. The 2018 parade will begin at 7:30 p.m., an hour later than previous years. The start time was changed to allow Oaklawn racing fans plenty of time to enjoy the live racing including The Rebel Stakes at Oaklawn Park, and still get downtown for the start of the parade. Morris Day and the Time will perform a free concert at the conclusion of the parade. On F

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom